Baidu
map

验尿筛查胃癌或能实现

2016-09-15 黄辛 朱凡 丁燕敏 中国科学报

由上海交大医学院附属瑞金医院教授朱正纲、于颖彦领衔的团队发现,尿液中可检测到胃癌标志物,预示着今后通过尿液也可筛查胃癌。相关成果日前发表于《癌症靶标》杂志。据悉,这项围绕胃癌患者尿液小分子标志物的创新性成果已申请国家发明专利。 由于尿液中的代谢物是小分子物质,原有的检测设备无法分析测试小分子化合物。瑞金医院研究人员从头摸索与建立分析方法,收集取样,并利用上海交大分析化学领域的精密仪器,对收

由上海交大医学院附属瑞金医院教授朱正纲、于颖彦领衔的团队发现,尿液中可检测到胃癌标志物,预示着今后通过尿液也可筛查胃癌。相关成果日前发表于《癌症靶标》杂志。据悉,这项围绕胃癌患者尿液小分子标志物的创新性成果已申请国家发明专利。

由于尿液中的代谢物是小分子物质,原有的检测设备无法分析测试小分子化合物。瑞金医院研究人员从头摸索与建立分析方法,收集取样,并利用上海交大分析化学领域的精密仪器,对收集到的样本进行初筛和第二步的定量分析验证。他们最终发现,氨基酸类和有机酸类共14种小分子化合物有生物学意义。这些新发现的胃癌尿液小分子化合物作为肿瘤标志物与血清传统肿瘤标志物对比分析,显示出良好的敏感性与特异性,其中有3种小分子在尿中的升高与胃癌不良预后有相关性。

据悉,该课题组此前已有胃癌血液标志物研究成果入选上海科技创新中心建设首批转化专利,由张江知识产权运营平台买断并进行试剂盒的制备与报批。朱正纲表示,目前正着手进行尿液新型小分子标志物的临床实用检测方法学探索,希望尽快使这项集医工、医理多学科的交叉性研究成果早日实现临床转化。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=131868, encodeId=27ef131868ca, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131869, encodeId=6e4f13186929, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131870, encodeId=07b21318e086, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131871, encodeId=55c81318e116, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131867, encodeId=d6b113186ec0, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:19:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-20 xyfg98

    很好的分享,赞不停!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=131868, encodeId=27ef131868ca, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131869, encodeId=6e4f13186929, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131870, encodeId=07b21318e086, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131871, encodeId=55c81318e116, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131867, encodeId=d6b113186ec0, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:19:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-20 xyfg98

    很好的分享,赞不停!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=131868, encodeId=27ef131868ca, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131869, encodeId=6e4f13186929, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131870, encodeId=07b21318e086, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131871, encodeId=55c81318e116, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131867, encodeId=d6b113186ec0, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:19:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-20 xyfg98

    很好的分享,赞不停!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=131868, encodeId=27ef131868ca, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131869, encodeId=6e4f13186929, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131870, encodeId=07b21318e086, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131871, encodeId=55c81318e116, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131867, encodeId=d6b113186ec0, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:19:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-20 xyfg98

    很好的分享,赞不停!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=131868, encodeId=27ef131868ca, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131869, encodeId=6e4f13186929, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131870, encodeId=07b21318e086, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131871, encodeId=55c81318e116, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:20:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131867, encodeId=d6b113186ec0, content=很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:19:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-20 xyfg98

    很好的分享,赞不停!

    0

相关资讯

周兆才博士:靶向YAP的个体化胃癌治疗

2016年5月13日至14日,(第三届)肿瘤与免疫治疗研讨会在上海好望角大饭店隆重召开,上海生科院生物化学与细胞生物学研究所周兆才研究员向大家介绍了靶向YAP的个体化胃癌治疗,演讲十分精彩。 周兆才研究员表示,胃癌是全世界范围内死亡率仅次于肺癌的恶性肿瘤,并且中国是一个胃癌发生大国,而针对胃癌的有效治疗手段非常有限。Hippo信号通路是近年来研究越来越多的癌症相关信号通路,在肿瘤发生发展和治

一图读懂胃癌!

胃的恶性肿瘤很多,如腺癌、淋巴癌、恶性肉瘤等。胃黏膜上皮组织长出的腺癌占了胃恶性肿瘤的绝大多数,达 50%~90%。因此通常胃癌指的就是这种恶性肿瘤。在胃癌早期70% 以上病人毫无症状,中晩期可出现上腹部疼痛、消化道出血、穿孔、幽门梗阻、消瘦、乏力、代谢障碍以及癌肿扩散转移而引起的相应症状。胃癌在任何年龄均可发生,以50~60岁居多。胃癌具有起病隐匿、早期常因无明显症状而漏诊、易转移与复发和预后差

Oncotarget:朱正纲教授发现验尿或能查胃癌

瑞金医院上海消化外科研究所朱正纲、于颖彦教授领衔的研究团队发现尿液中可以检测到胃癌标志物。这预示着今后通过尿液就可以筛查胃癌。该成果对于实现胃癌的“无创化”诊断、提高胃癌早期发现、早期治疗有着积极的意义。这项研究成果在国际癌症研究权威刊物《癌症靶标(Oncotarget)》发表。据悉,中国是胃癌的高发区,早期胃癌症状并不明显,而国人对胃镜检查心怀恐惧,往往被查出胃癌时已是中晚期,错失最佳手术治疗时

邱海波博士带您看:ASCO胃癌研究热点!

美国临床肿瘤学(ASCO)2016年会在芝加哥举行,全世界肿瘤研究者的目光都集中于此,胃癌作为一个发病率高影响人群广而受到了广泛关注,总结今年ASCO年会的摘要,梳理胃癌领域的研究热点主要集中在如下领域。 免疫治疗 目前,免疫治疗在肿瘤领域中研究火热,胃癌作为大病种也不例外,从今年的ASCO来看,免疫治疗的研究就有4项,其中3项是1/II期研究,结果喜忧参半

三大指南共识权威发布,HER2检测首度纳入胃癌诊治必检项

2016年5月13-15日,由中国抗癌协会胃癌专业委员会主办的第十一届全国胃癌学术会议(CGCC)暨第四届阳光长城肿瘤学术会议在北京国家会议中心隆重召开。会议期间,中国抗癌协会发布了第二版《人表皮生长因子受体2阳性晚期胃癌分子靶向治疗的中国专家共识》(后文简称《胃癌抗HER2共识》)和《NCCN消化系统肿瘤临床实践指南》中文版(后文简称《NCCN指南》中文版),就胃癌治疗提供了最新的专家共识及

2016中国胃癌重要指南共识汇总

近期有关胃癌研究领域的大量基础和临床研究,从不同方向、不同角度对胃癌及其并发症的临床诊治进行了深入研究,为胃癌的临床管理寻找最新方向。本文就近期胃癌领域重要的指南共识进行回顾。重要指南与共识1,《人表皮生长因子受体2阳性晚期胃癌分子靶向治疗的中国专家共识》(后文简称《胃癌抗HER2共识》)指南要点:1).指出HER2与临床病理特征有关,但不足以独立作为判断胃癌患者预后的标志物;再次强调HER2是胃

Baidu
map
Baidu
map
Baidu
map